SK Plasma, which is constructing a plasma fractionation plant in Indonesia, announced on the 10th that it will fully commence its contract manufacturing organization (CMO) business for blood products in Indonesia.
According to SK Plasma, the Indonesian plasma for CMO purposes arrived at the Andong plant. The company plans to supply blood products in CMO form until the completion of its blood product production facility in Indonesia.
Earlier, SK Plasma established a joint venture, SK Plasma Core, with sovereign wealth funds from Indonesia. Currently, it is constructing a blood product production facility capable of fractionating 600,000 liters of plasma annually in the Karawang industrial complex in Jakarta, aiming to be operational by the fourth quarter of 2026.
The company stated, "This is the first time for Indonesia to import plasma, and it will be used for the production of albumin and immunoglobulin products starting in the first half of the year."
During the CMO period, the company plans to provide professional technical training in quality control and production to local personnel at the Andong plant, fostering them as bio-experts who can stably produce and manage pharmaceuticals after the facility is completed.
Kim Seung-joo, CEO of SK Plasma, noted, "Given the characteristics of pharmaceuticals made from blood, it is recommended to produce pharmaceuticals using domestic plasma; however, producing blood products requires advanced technology and infrastructure, so there is significant potential in the CMO market," and he added, "Based on the technology and solutions SK Plasma possesses, we plan to expand our global operations through collaboration with countries in need of production technology, including CMO and local technology transfer."